SC-21017 V CLEAR SC-2526 V RED SC-24783 V OD

F SPORT RED R377 PPC4TF V.2 F SPORT RED R377 MAGNUM V.2 CHATEAU S1G4 MAGNUM V.2

SC-1291 V RED SC-1291 V GREEN SC-1327 V RED

E-733 V BLACK SC-2862 V RED SC-2888 V BLUE

D is t. ) R P M P P G K W R F U L A V Y G C P IF F F M C H X L H U N E M N F O E E C L K R A S C L A S H C E G R A A LB Median: 5%Median: 3% Source: Peer data per Bloomberg market data as of February 5, 2021 Avient reflects 2021 estimated revenue of $4,100M and excludes one-time synergy capture CAPEX ($20M) Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 83% Median: 76% HIGH FREE CASH FLOW CONVERSION Avient reflects 2021 estimated EBITDA of $510M and excludes one-time synergy capture CAPEX ($20M) Source: Peer data per Bloomberg market data as of February 5, 2021 85 87 86 86 81 81 59 92 88 81 79 79 79 76 76 75 73 67 67 64 60 7 A vi en t P P G K W R R P M F U L A V Y G C P IF F F M C U N V R H X L E M N B N R E C L C E A S H F O E G R A H U N K R A S C L A L B Source: Peer data per Bloomberg market data as of February 5, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation implies an EBITDA multiple that is significantly below specialty formulator peers and our historic valuations, when the company had considerable exposure to more cyclical and challenging end markets. With the Clariant Masterbatch acquisition and divestment of the PP&S business, our exposure is now concentrated in less-cyclical and high-growth markets, with increased geographic diversification and a more specialized portfolio that can significantly expand EBITDA margins. 24 Avient reflects 2021 estimated EBITDA of $510M OUR VALUATION VERSUS PEERS Avient Specialty Formulators Other Chemical/Specialty Companies 9.5 21.1 13.2 13.2 12.0 12.0 9.7 25.2 23.1 14.7 13.5 12.9 11.0 11.0 11.0 10.2 9.6 9.3 9.3 9.1 8.6 8.3 A vi en t K W R A V Y R P M G C P P P G F U L A L B E C L H X L IF F F M C G R A B N R F O E A S H C E S C L U N V R E M N H U N K R A Median: 11.0xMedian: 12.6x SUMMARY: WHY INVEST IN AVIENT?

√ C 0689690410 AVIENT COLORANTS MALAYSIA SDN. BHD. 9-3A-1, JLN METRO PERDANA BARAT 1, TMN USAHAWAN KEPONG UTARA, 52100 KUALA LUMPUR WP KUALA LUMPUR A V I E N T C O L O R A N T S M A L A Y S I A S D N .

AVIENT CORPORATION S E C O N D Q U A R T E R 2 0 2 3 R E S U L T S (NYSE: AVNT) J U LY 2 7 , 2 0 2 3 DISCLAIMER Forward-Looking Statements Certain statements contained in or incorporated by reference into this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Additionally, Adjusted EPS excludes the impact of special items and amortization expense associated with intangible assets. 2 COMPOSITES PORTFOLIO D Y N E E M A ® E X P A N D S O U R E N G I N E E R E D F I B E R S A N D P A N E L S T E C H N O L O G Y LFT Tapes Laminates/Panels Shapes Pultrusion Engineered Fibers 4 DEFENSE TELECOMMUNICATIONS ENERGY TRANSPORTATION Military • Law Enforcement First Responders Body Armor • Helmets Vehicle Protection Sustainable Infrastructure Offshore Wind Electrical Grid Protection EV Battery Components Commercial Laminates Body & Trim • Air Cargo and Railroad Car Panels 5G Applications Fiber Optic Cables Satellite Communications Connectors and Components 5 COMPOSITES SERVE DIVERSIFIED END MARKETS INDUSTRIAL Lifting Slings • Aquaculture High Pressure Pipe Conveyer Springs Q 2 P ER FO RM A N CE Q2 2023 PERFORMANCE VS. Avient reflects 2023 adjusted EBITDA guidance of $525M and estimated run-rate CAPEX of $110M. 2023E (%) 23 79 90 84 83 76 73 88 82 77 74 72 67 57 20 A vi en t K W R P P G F U L A V Y R P M F M C C E H X L E C L A S H H U N E M N S C L Avient Specialty Formulators Other Specialty / Chemical Companies MULTIPLE EXPANSION Source: Peer data per Bloomberg as of July 21, 2023 Note: Avient reflects 2023 adjusted EBITDA guidance of $525M and closing share price of $40.93.

MAJOR TIER 1 SUPPLIER C O N N E C T O R C O V E R • EMI-shielding performance at frequencies from 30 MHz up to 2 GHz • Excellent dimensional stability • Must meet robust mechanical property targets including tensile strength and elongation at break • Worked in close collaboration with the OEM from the start of the development process in order to fully understand their key requirements • Developed a customized material providing the required EMI-shielding performance which, removing the need for secondary metallization manufacturing processes, reduced cycle time Surround™ NN- 14 NICF SIP Black Formulation KEY REQUIREMENTS WHY AVIENT?

Colorants and Additives for Wire & Cable – N. Explore our full portfolio for Wire & Cable applications (N.

D is t. ) K W R P P G A V Y F U L R P M G C P F M C H X L H U N E C L A S H E M N C E S C L Source: Peer data per Bloomberg market data as of October 25, 2021 Avient reflects 2021 estimated revenue of $4,750M and estimated CAPEX of $80M (excludes one-time synergy capture CAPEX of $20M) Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA HIGH FREE CASH FLOW CONVERSION Avient reflects 2021 estimated EBITDA of $580M and estimated CAPEX of $80M (excludes one-time synergy capture CAPEX of $20M) Source: Peer data per Bloomberg market data as of October 25, 2021 86 92 85 82 79 77 74 89 83 82 80 79 79 78 78 72 33 A vi en t K W R P P G A V Y F U L R P M G C P F M C U N V R C E H X L B N R A S H E C L E M N H U N S C L A L B (12) Source: Peer data per Bloomberg market data as of October 25, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation with updated guidance implies an EBITDA multiple that is below specialty formulator peers and the median of other selected chemical / specialty companies. With the Clariant Color business acquisition and divestment of the PP&S business, our exposure is now concentrated in less-cyclical and high-growth markets, with increased geographic diversification and a more specialized portfolio that can significantly expand EBITDA margins. 24 Avient reflects 2021 estimated EBITDA of $580M OUR VALUATION VERSUS PEERS Avient Specialty Formulators Other Chemical/Specialty Companies 11.0 18.3 16.3 15.4 14.5 11.6 11.1 36.2 28.0 24.9 13.0 11.5 11.3 10.0 9.2 8.8 7.7 6.7 A vi en t K W R P P G A V Y R P M F U L G C P A L B H X L E C L A S H F M C B N R S C L U N V R E M N C E H U N SUMMARY: WHY INVEST IN AVIENT?